HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daniela Pietrobon Selected Research

voltage-dependent calcium channel (P-Q type)

1/2015Abnormal cortical synaptic transmission in CaV2.1 knockin mice with the S218L missense mutation which causes a severe familial hemiplegic migraine syndrome in humans.
9/2014Mechanism underlying unaltered cortical inhibitory synaptic transmission in contrast with enhanced excitatory transmission in CaV2.1 knockin migraine mice.
7/2013Calcium channels and migraine.
7/2010CaV2.1 channelopathies.
6/2010Insights into migraine mechanisms and CaV2.1 calcium channel function from mouse models of familial hemiplegic migraine.
1/2010High cortical spreading depression susceptibility and migraine-associated symptoms in Ca(v)2.1 S218L mice.
3/2009Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice.
11/2008Inherited neuronal ion channelopathies: new windows on complex neurological diseases.
4/2007Familial hemiplegic migraine.
6/2005Function and dysfunction of synaptic calcium channels: insights from mouse models.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Daniela Pietrobon Research Topics

Disease

16Migraine with Aura (Familial Hemiplegic Migraine)
01/2021 - 02/2002
12Migraine Disorders (Migraine)
01/2021 - 03/2004
5Epilepsy (Aura)
07/2013 - 03/2004
4Nervous System Diseases (Neurological Disorders)
01/2021 - 02/2002
4familial type 2 Hemiplegic migraine
01/2021 - 06/2011
4Channelopathies
07/2010 - 02/2002
2Spinocerebellar Ataxias (Spinocerebellar Ataxia)
07/2010 - 02/2002
2Type 2 Episodic Ataxia
07/2010 - 02/2002
2Ataxia (Dyssynergia)
11/2008 - 02/2002
1Headache (Headaches)
01/2020
1Chronic Pain
11/2008
1Pain (Aches)
11/2008
1Generalized Epilepsy with Febrile Seizures Plus
11/2008
1Brain Edema (Cerebral Edema)
05/2005
1Craniocerebral Trauma (Head Injury)
05/2005
1Coma (Comas)
05/2005
1congenital stationary Night blindness
02/2002
1Absence Epilepsy (Childhood Absence Epilepsy)
02/2002

Drug/Important Bio-Agent (IBA)

13voltage-dependent calcium channel (P-Q type)IBA
01/2015 - 10/2002
6Glutamic Acid (Glutamate)FDA Link
01/2021 - 03/2011
5Adenosine Triphosphatases (ATPase)IBA
01/2020 - 04/2007
5Calcium Channels (Calcium Channel)IBA
07/2013 - 02/2002
3Q-Type Calcium Channels (Q-Type Calcium Channel)IBA
09/2014 - 02/2002
3Ion Channels (Ion Channel)IBA
01/2013 - 11/2008
2N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
01/2021 - 03/2011
2Protein Isoforms (Isoforms)IBA
01/2016 - 06/2011
2Neurotransmitter Agents (Neurotransmitter)IBA
11/2008 - 04/2007
2CalciumIBA
11/2008 - 02/2002
1N-Methylaspartate (NMDA)IBA
01/2020
1Ceftriaxone (Ceftriaxon)FDA LinkGeneric
01/2016
1NeuropeptidesIBA
01/2013
1SodiumIBA
11/2008
1Sodium Channels (Sodium Channel)IBA
11/2008
1Retinaldehyde (Retinal)IBA
02/2002